Fundraising FoxMythic Therapeutics
DefunctWaltham, US · Founded 2018 · Delaware corporation · 6 known investors
Find your way into Mythic Therapeutics
Sign up to see every warm intro you have to Mythic Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Mythic Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Mythic Therapeutics was a clinical-stage biotech developing next-generation antibody-drug conjugates for cancer using its proprietary FateControl technology. Its lead candidate, MYTX-011, targeted cMET in a Phase 1 trial for non-small cell lung cancer.
Founders & leadership
Mythic Therapeutics was founded in 2018 by Brian Fiske.
BF
Brian FiskeFounder
GE
George EliadesChief Executive OfficerHe brings over 20 years of leadership experience in biotech and pharmaceuticals, with expertise spanning M&A, strategy development, commercialization, and cost optimization across oncology, ophthalmology, and specialty pharmaceutical categories.
SP
Sandra PooleChief Operating Officer2020–2025Sandra Poole is an executive in biopharma with more than 25 years of experience in drug development and organizational leadership. She has held senior roles at Genzyme/Sanofi, ImmunoGen, LogicBio, and Mythic Therapeutics, with expertise spanning oncology, rare diseases, manufacturing, and regulatory strategy across preclinical through commercial stages.
AN
Alex NicholsNamed on SEC filing
Board
BR
PH
Peter HechtBoard director
Investors · 6
Foresite Capitallisted by Foresite CapitalWest Hollywood
How we know: Foresite Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
Hemi Ventures, Llclisted by Hemi Ventures, LlcPalo Alto · $250K – $500Kvia Amy Gu · inferred
How we know: Hemi Ventures, Llc's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
Lifeforce Capitallisted by Lifeforce CapitalChevy Chase · $500K – $5M
How we know: Lifeforce Capital's portfolio page · the VCSheet dataset · Not right? Tell us
Nat Turnerlisted by Nat TurnerNew York City
How we know: Nat Turner's portfolio page · Not right? Tell us
Viking Globallisted by Viking GlobalStamford
How we know: Viking Global's portfolio page · Not right? Tell us
Refactor CapitalreportedBurlingame · $1M – $2M
How we know: the VCSheet dataset · Not right? Tell us
Funding
SEC filings, press & company announcements$53.5M disclosed across 3 of 4 rounds · 2018–2024
- Undisclosed amountSeries BDec 2021Source ↗
▶$29.9MraisedDec 2024 · 30 investors · BiotechnologyRule 506(b)
▶$29.9MraisedDec 2024 · 30 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- George EliadesExecutive Officer, Director
- Bryan RobertsDirector
- Peter HechtDirector
- Sandra PooleExecutive Officer
- Brian FiskeExecutive Officer, Director
- Offering amount
- $30.4M
- Amount sold
- $29.9M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.7MraisedAug 2020 · 21 investors · BiotechnologyRule 506(b)
▶$4.7MraisedAug 2020 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alex NicholsExecutive Officer, Director, Promoter
- Brian FiskeExecutive Officer, Director, Promoter
- Offering amount
- $4.7M
- Amount sold
- $4.7M
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$18.8MraisedAug 2020 · 18 investors · BiotechnologyRule 506(b)
▶$18.8MraisedAug 2020 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jason HansonDirector
- Josh KopelmanDirector
- Bryan RobertsDirector
- Alex NicholsExecutive Officer, Director, Promoter
- Brian FiskeExecutive Officer, Director, Promoter
- Offering amount
- $18.8M
- Amount sold
- $18.8M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Dialectic TherapeuticsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
SoluSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Context TherapeuticsContext Therapeutics develops clinical-stage T cell engaging bispecific antibody therapies for the treatment of solid tumors. Its pipeline targets antigens such as Claudin 6, mesothelin, and Nectin-4 to direct the immune system against difficult-to-treat cancers.
Companies working in the same space as Mythic Therapeutics.
Frequently asked questions
- What does Mythic Therapeutics do?
- Mythic Therapeutics was a clinical-stage biotech developing next-generation antibody-drug conjugates for cancer using its proprietary FateControl technology. Its lead candidate, MYTX-011, targeted cMET in a Phase 1 trial for non-small cell lung cancer.
- Who founded Mythic Therapeutics?
- Mythic Therapeutics was founded by Brian Fiske in 2018.
- Who are Mythic Therapeutics's investors?
- Mythic Therapeutics's investors include Foresite Capital, Hemi Ventures, Llc, Lifeforce Capital, Nat Turner, Viking Global, Refactor Capital.
- How much funding has Mythic Therapeutics raised?
- Mythic Therapeutics has disclosed $53.5M raised across 3 of its 4 known rounds.
- Where is Mythic Therapeutics headquartered?
- Mythic Therapeutics is headquartered in Waltham, US.